News | November 18, 2020

Rivaroxaban is Comparable to Warfarin for Bioprosthetic Mitral Valves and AF

RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm

RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm

November 18, 2020 — The primary results from the RIVER Trial, Rivaroxaban for Valvular Heart disease and Atrial Fibrillation, show that rivaroxaban is comparable to warfarin, which is currently the standard of care anticoagulant prescribed for patients with bioprosthetic mitral valves, according to late-breaking research presented today at the 2020 American Heart Association (AHA) Scientific Sessions. 

Researchers said clinicians have used direct oral anticoagulants (DOACs) such as rivaroxaban off-label for patients with bioprosthetic mitral valves who have atrial fibrillation (AF) or flutter.

The RIVER trial followed 1,005 patients from 49 sites in Brazil who had a bioprosthetic mitral valve and atrial fibrillation or flutter for 12 months. Patients were randomized to rivaroxaban 20 mg once daily or the vitamin K antagonist anticoagulant warfarin (dose-adjusted to an international normalized ratio (INR) between 2.0-3.0). The primary endpoint was a composite of death, major cardiovascular events (stroke, transient ischemic attack, systemic embolism, valve thrombosis or hospitalization for heart failure) or major bleeding over 12 months.

“This is the largest trial designed to evaluate the safety and efficacy of direct oral anticoagulants in patients with bioprosthetic mitral valves and atrial fibrillation or flutter. Earlier trials of direct oral anticoagulants vs. warfarin for atrial fibrillation or flutter together included fewer than 200 patients with bioprosthetic mitral valves,” said lead study author Otavio Berwanger, M.D., Ph. D., a cardiologist and epidemiologist, and the director of the Research Institute Hcor, Heart Hospital (Hospital de Coracao) in Sao Paulo, Brazil.

Patients who received rivaroxaban had an average of almost one year (347.5 days) free from the primary endpoint, similar to those treated with warfarin (340.1 days).

“Additionally, our confidence interval likely excluded an effect size larger than 1.4 days free from events favoring warfarin, clearly demonstrating the non-inferiority effect of rivaroxaban in this clinical setting,” Berwanger said. “There was a similarly nonsignificant numeric trend favoring rivaroxaban for most secondary endpoints, however, the incidence of stroke was lower in the rivaroxaban than in the warfarin group. Importantly, safety events such as valve thrombosis, major/non-major clinically relevant and total bleeding were not statistically different between the rivaroxaban and warfarin groups.”

A subgroup analysis of 18.8% of RIVER patients with bioprosthetic mitral valve implantation within the prior three months showed a mean of 35.1 days longer without evidence of the primary outcome compared to patients treated with warfarin.

“The results from the RIVER Trial are consistent with previous research, including ROCKET and other pivotal trials of DOACs, and can inform clinical practice for patients with bioprosthetic mitral valves,” Berwanger said. “For a subgroup of patients with a mitral valve replacement within the last three months, rivaroxaban was statistically and clinically superior to warfarin.”

The main study limitations are the open-label design, and the fact that the findings cannot be extrapolated to patients with a bioprosthetic aortic valve in the aortic position, or  for patients with mitral stenosis or with mechanical valves. Trials in these populations are ongoing.

Co-authors are Renato D, Lopes Sr., M.D., Ph.D.; Pedro Gabriel G. de Barros E. Silva, M.D., Ph.D.; Helio P. Penna Guimaraes, M.D., Ph.D.; Flavia C.S. Kojima, B.Sc., Viviane B. Bezerra Campos, B.Sc.; Renato H. Nakagawa, B.S.; Lucas Petri Damiani, M.Sc.; Denise Paisani, Ph.D.; Eliana Santucci, Ph.D.; Nanci Valeis, L.LB.; Ligia N. Laranjeira, Ph.D.; Ricardo Pavanello, M.D., Ph.D.; and Alexandre Cavalcanti, M.D., Ph.D. Author disclosures are on the abstract

The trial was funded by the Brazilian Ministry of Health (PROADI-SUS Program) and Bayer.

Find other AHA news, video and late-breakers

Related article on NOACs, Advantages and Disadvantages of Novel Oral Anticoagulants.

Related Content

The American Heart Association, AHA, late-breaking sessions, trials, studies. #AHA #AHA20 #AHA2020
Feature | AHA | November 20, 2020 | Dave Fornell, Editor
Here is a list of the American Heart Association (...
The American Heart Association (AHA) has cancelled its in-person annual meeting due to COVID-19 and plans to host a virtual, online meeting instead.

The American Heart Association (AHA) has cancelled its in-person annual meeting due to COVID-19 and plans to host a virtual, online meeting instead.

News | AHA | July 15, 2020
July 15, 2020 – The last major cardiovascular conference to go virtual in 2020 due to the...
cardiac arrest cath lab
News | AHA | November 21, 2019
November 21, 2019 — People who experience cardiac arr...
heart disease
News | AHA | November 20, 2019
November 20, 2019 — Heart attack survivors may have an increased risk of developing cancer compared to people without
 Assorted pastries
News | AHA | November 20, 2019
November 20, 2019 — Ultra-processed foods, which account for more than half of an average American’s daily calories,
marijuana leaf
News | AHA | November 20, 2019
November 20, 2019 — Frequent cannabis (marijuana) use among young people was linked to an increased risk of...
In the ISCHEMIA study, patients were randomized into one of two groups: a conservative strategy or an invasive strategy. Illustration by NYU Langone staff

In the ISCHEMIA study, patients were randomized into one of two groups: a conservative strategy or an invasive strategy. Illustration by NYU Langone staff 

Feature | AHA | November 19, 2019
November 19, 2019 — After 12 years of collecting data, the results of the landmark ISCHEMIA (International Study of C
The American Heart Association, AHA, 2019 meeting late breaking trials and key studies on cardiovascular science.
Feature | AHA | November 19, 2019 | Dave Fornell, Editor
Here is a list of the key late-breaking clinical study presentations at the 2019 American Heart Association (AHA)...